SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.

“The real-world data we have gathered illuminate the under-acknowledged burden of AMN: affected individuals are experiencing more comorbidities, higher rates of hospitalization, substantially more prescription fills, higher overall healthcare costs, and poorer clinical outcomes than their peers,” said Tom Anderson, chief executive officer and director, SwanBio Therapeutics. “These findings demonstrate that the standard of care for AMN is not enough – these patients need and deserve more.”

SwanBio’s study was based on a retrospective review of commercial insurance and Medicare claims, comparing resource utilization and health outcomes of men and women living with AMN to those without AMN from similar demographic groups.

Key findings include:

• Adults with AMN experienced more comorbidities, including peripheral vascular disease (men: 4.6% vs. 0.9%; women: 2.2% vs. 0.5%), chronic pulmonary disease (men: 6.3% vs. 2.6%; women: 6.0% vs. 3.6%), and liver disease (men: 5.6% vs. 0.8%; women: 3.2% vs. 0.9%).
• A significantly larger proportion of people living with AMN had at least one hospital admission (men: 32.0% vs. 6.1%; women: 23.2% vs. 7.2%).
• Commercially insured adults living with AMN 18-64 years old had dramatically higher annualized all-cause direct medical costs; this is especially true for men with AMN, whose medical costs are approximately 10 times higher per person per year. Men living with AMN also utilized significantly more prescription medications (18.1 vs. 5.4 pharmacy fills per year).
• Among those living with AMN between the ages of 18 and 64 enrolled in Medicare, mortality rates were higher (men: 5.3 times higher at 39.3% vs. 7.4%; women: 15.7% vs. 4.9%) and age at death was younger (9 years younger for men; 3 years younger for women).

These findings were recently presented at the American Academy of Neurology (AAN) Annual Meeting and International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. For more information, visit swanbiotx.com/investors-and-media/events-and-presentations/.

 

Source:swanbiotx.com

Report Abuse